You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 3, 2025

CLINICAL TRIALS PROFILE FOR ADENOSINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for adenosine

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00000395 ↗ Antifolate Effectiveness in Arthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1996-09-01 This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
NCT00000395 ↗ Antifolate Effectiveness in Arthritis Completed Office of Dietary Supplements (ODS) Phase 2 1996-09-01 This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
NCT00000395 ↗ Antifolate Effectiveness in Arthritis Completed University of Alabama at Birmingham Phase 2 1996-09-01 This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for adenosine

Condition Name

5117160-50510152025303540455055Coronary Artery DiseaseAsthmaHealthy[disabled in preview]
Condition Name for adenosine
Intervention Trials
Coronary Artery Disease 51
Asthma 17
Healthy 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

736756001020304050607080Coronary Artery DiseaseMyocardial IschemiaCoronary Disease[disabled in preview]
Condition MeSH for adenosine
Intervention Trials
Coronary Artery Disease 73
Myocardial Ischemia 67
Coronary Disease 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for adenosine

Trials by Country

+
Trials by Country for adenosine
Location Trials
United States 951
China 82
Canada 74
United Kingdom 60
Italy 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for adenosine
Location Trials
California 64
Texas 49
Maryland 49
New York 48
Pennsylvania 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for adenosine

Clinical Trial Phase

56.0%34.4%9.6%0020406080100120Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for adenosine
Clinical Trial Phase Trials
Phase 4 122
Phase 3 75
Phase 2/Phase 3 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

66.1%20.6%13.3%0050100150200250300CompletedRecruitingNot yet recruiting[disabled in preview]
Clinical Trial Status for adenosine
Clinical Trial Phase Trials
Completed 308
Recruiting 96
Not yet recruiting 62
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for adenosine

Sponsor Name

trials05101520253035National Cancer Institute (NCI)Radboud UniversityAstraZeneca[disabled in preview]
Sponsor Name for adenosine
Sponsor Trials
National Cancer Institute (NCI) 34
Radboud University 24
AstraZeneca 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

70.1%22.8%7.0%00100200300400500600700OtherIndustryNIH[disabled in preview]
Sponsor Type for adenosine
Sponsor Trials
Other 707
Industry 230
NIH 71
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Adenosine Market Analysis and Financial Projection

Adenosine: Clinical Trials, Market Analysis, and Projections

Introduction to Adenosine

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule. It plays a crucial role in various biological processes, including energy transfer, signal transduction, and as a neuromodulator. In the context of pharmaceuticals and medical research, adenosine and its analogs or antagonists are being explored for their therapeutic potential in several diseases.

Clinical Trials Update

Adenosine Antagonists in Oncology

Adenosine antagonists are gaining significant attention in oncology due to their ability to modulate the immune response. Here are some key updates from ongoing clinical trials:

  • iTeos Therapeutics' Inupadenant: In the Phase 2 A2A-005 trial, inupadenant combined with carboplatin and pemetrexed showed a 63.9% overall response rate (ORR) and a median progression-free survival (PFS) of 7.7 months. However, despite these encouraging results, iTeos has decided not to invest further in this program due to insufficient clinical activity[1].

  • Corvus Pharmaceuticals' Ciforadenant: Corvus is conducting a Phase 1b/2 trial evaluating ciforadenant in combination with ipilimumab and nivolumab for metastatic renal cell cancer (RCC). The interim analysis has met the efficacy threshold, indicating a promising direction for this combination therapy[4].

  • Other Pipeline Therapies: DelveInsight's report highlights several other adenosine antagonists in various stages of clinical development, including Etrumadenant, PORT-6, PORT 7, and PBF-680. These therapies are being assessed for their potential in treating neurodegenerative diseases, oncology, and cardiovascular disorders[5].

Market Analysis

Global Adenosine Market

The global adenosine market is diverse, encompassing various applications and regions.

  • Market Size and Growth: The adenosine market has seen significant growth, with forecasts indicating continued expansion. For instance, the adenosine triphosphate (ATP) assays market, a related segment, is expected to grow from $1.77 billion in 2023 to $3.01 billion by 2028 at a CAGR of 11.2%[3].

  • Regional Analysis: The market is segmented across regions including North America, South America, Asia & Pacific, Europe, and the Middle East & Africa. Key countries such as the United States, China, Japan, India, and Germany are significant contributors to the global market[2].

  • Applications: Adenosine is used in various sectors, including pharmaceuticals, cosmetics, and others. The pharmaceutical sector is a major driver, with applications in drug discovery, clinical diagnostics, and therapeutic development[2].

Key Players

The adenosine market is characterized by the presence of several key players:

  • Aceto Corporation, Yamasa, Nantong Sane Biological, and Meihua Group are among the major companies involved in the production and distribution of adenosine[2].

  • Biopharmaceutical Companies: Companies like iTeos Therapeutics, Corvus Pharmaceuticals, Arcus Biosciences, and Portage Biotech are actively involved in the development of adenosine antagonists for therapeutic use[5].

Market Projections

Growth Drivers

Several factors are driving the growth of the adenosine market:

  • Advancements in Biomedical Research: Continued advancements in biomedical research, particularly in the fields of immunotherapy and oncology, are fueling the demand for adenosine and its analogs[3].

  • Expansion in Clinical Diagnostics: The increasing adoption of adenosine-based assays in clinical diagnostics is another significant driver. These assays are crucial for monitoring cellular health and detecting diseases early[3].

  • Technological Innovations: Innovations in formulation and delivery systems are expected to enhance the efficacy and safety profiles of adenosine-based therapies, leading to increased adoption[5].

Market Restraints and Opportunities

  • Regulatory Approvals: The need for regulatory approvals can act as a restraint. However, successful clinical trials and approvals will bolster market credibility and expand demand[5].

  • Therapeutic Applications: The identification of novel therapeutic applications, such as in neurodegenerative diseases and cardiovascular disorders, presents significant opportunities for growth[5].

Forecast Data

  • The global adenosine market is forecasted to continue its growth trajectory, with the ATP assays market alone expected to reach $3.01 billion by 2028[3].

  • The adenosine antagonists pipeline is robust, with multiple therapies in various stages of clinical development. This pipeline activity is expected to drive market growth in the coming years[5].

Key Takeaways

  • Clinical Trials: Adenosine antagonists are showing promising results in clinical trials, particularly in oncology, with therapies like inupadenant and ciforadenant demonstrating potential.

  • Market Growth: The global adenosine market is expected to grow significantly, driven by advancements in biomedical research, expansion in clinical diagnostics, and technological innovations.

  • Key Players: Major biopharmaceutical companies are actively involved in the development and commercialization of adenosine-based therapies.

  • Regulatory and Therapeutic Opportunities: Successful regulatory approvals and the identification of new therapeutic applications will be crucial for market expansion.

FAQs

What are the current clinical trials focusing on adenosine antagonists?

Current clinical trials are focusing on adenosine antagonists like inupadenant and ciforadenant, primarily in the context of oncology. These trials are evaluating the efficacy of these compounds in combination with other therapies for various cancers.

Which companies are leading the development of adenosine antagonists?

Companies such as iTeos Therapeutics, Corvus Pharmaceuticals, Arcus Biosciences, and Portage Biotech are among the key players in the development of adenosine antagonists.

What are the major applications of adenosine in the pharmaceutical sector?

Adenosine is used in drug discovery, clinical diagnostics, and therapeutic development. It is particularly significant in immunotherapy and oncology.

What is the forecasted growth of the adenosine market?

The adenosine market, including segments like ATP assays, is expected to grow significantly, with forecasts indicating a market size of $3.01 billion by 2028 for ATP assays alone.

What are the key drivers of the adenosine market growth?

The growth is driven by advancements in biomedical research, expansion in clinical diagnostics, technological innovations, and the identification of new therapeutic applications.

Sources

  1. iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data - Investors.iTeosTherapeutics.
  2. Worldwide Adenosine Industry to 2025 - BusinessWire.
  3. Adenosine Triphosphate (ATP) Assays Global Market Report 2024 - TheBusinessResearchCompany.
  4. Corvus Pharmaceuticals Provides Business Update and Reports Financial Results - CorvusPharma.gcs-web.
  5. Adenosine Antagonists Clinical Trial Pipeline Analysis - GlobeNewswire.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.